2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4554 Real-world patterns, duration, and outcomes of post-transplant maintenance therapy in multiple myeloma: An ASH research collaborative data hub analysis

Barry Paul, MD, MS, Arash Velayati, MD, MBA2, Susan Geyer, PhD3, Levi Pederson, MS4, Peyton Schumacher5, Travis Dockter, MS6, Todd Kennedy, BA7, Michael Riotto, BS8, Emily Semmel, MS9, Shandra James, DNP10, Saad Z. Usmani, MD11, Shaji Kumar, MD12, Samuel Rubinstein, MD MSCI13, Kenneth Anderson, MD14, William Wood, MD, MPH15, Shambavi Richard, MD16, Manisha Bhutani, MD17, Andrew Kin, MD18, Venkatesh Charya, MS19, Andy Coracy, N/A20, Anita D'Souza Jr, MD21, Jodi Lipof, MD22, Suzanne Hayman, MD23, Hamza Hashmi, M.D.24, Ajay K Nooka, MD, MPH25, Jiefu Wang, PhD26, Poy Theprungsirikul, MD27, Aaron S Rosenberg, MD28
1 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
2 University of California Davis, Sacremento, California, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 ASH Research Collaborative Patient Collaboration Team, Coto de Caza, California, United States
8 ASH Research Collaborative Patient Collaboration Team, Washington, District of Columbia, United States
9 ASH Research Collaborative, Washington, District of Columbia, United States
10 ASH Research Collaborative, Washington, District of Columbia, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
16 Mount Sinai Tisch Cancer Center, New York, New York, United States
17 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
18 Karmanos Cancer Center, Detroit, Michigan, United States
19 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
20 Washington University in Saint Louis, Saint Louis, Missouri, United States
21 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
22 UCSF Health, San Francisco, California, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Emory University School of Medicine, Atlanta, Georgia, United States
26 University of California Davis School of Medicine, Davis, California, United States
27 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
28 University of California Davis, Sacremento, California, United States

Background: Continuous maintenance (mx) therapy until progression after autologous stem cell transplant (ASCT) remains the standard of care for transplant eligible newly diagnosed multiple myeloma (NDMM) with phase III trials and large meta-analyses demonstrating both progression free (PFS) and overall survival (OS) benefits. However, several studies suggest most patients (pts) discontinue mx therapy prior to progression. We utilized a large academic, real-world database to assess mx duration and to assess the outcomes of pts who discontinued mx prior to relapse, including time to next treatment (TTNT), and efficacy of subsequent therapy.

Methods: Using the ASH Research Collaborative (ASH RC) Data Hub, we retrospectively examined pts with NDMM who received ≤2 lines of induction, ASCT, and post-ASCT mx with either lenalidomide (len) monotherapy (LM) or a len doublet (LD: either len + a proteasome inhibitor [PI] or len + an anti-CD38 mAb) with ≥3 months (m) of follow-up. We evaluated TTNT, time to subsequent progression and/or death (PFS2) in all pts; comparing outcomes by mx duration (< 12 m vs ≥ 12 m), and those who progressed while on, or within 60 days of stopping mx compared to those that progressed beyond 60 days. Kaplan-Meier and log-rank statistics stratified by institution were used to evaluate differences in time-to-event outcomes.  

Results: A total of 179 pts met inclusion criteria: 38 (21%) pts received LD (24 len + PI, 14 len + anti-CD38 mAb) and 141 (79%) received LM. The groups were balanced by gender, age at start of mx, and best response prior to mx initiation. Black or African American pts represented 23% of the cohort and were balanced between mx type and duration. More high-risk pts (defined as presence of del(17p), t(4;14), or t(14;16)) received LD compared to LM (67% vs 21% p=0.003). The overall median duration of mx in our cohort was 18.4 m and was longer in LM pts (20.6m vs 11.5m; p=0.01); 39.7% of pts received ≥ 12m of mx.

Across the cohort, 148 (83%) pts received subsequent treatment and 109 (61%) had a reported PFS event. Median PFS (mPFS) for all pts was 49.2m from the start of mx. Unadjusted mPFS for pts on LM was 56.3m vs 30.5m for LD therapy (p=0.057).

Median TTNT for LM pts was 37.5m, vs 11.6m for those on LD (p < 0.0001). To assess the effect of mx duration on TTNT, we stratified analyses on pts who received < 12m of mx (49 LM vs 20 LD), and pts who received ≥ 12m of mx (92 LM vs 18 LD). TTNT favored LM in both cohorts (< 12m: 10.8 vs 6.1m, p=0.001; ≥ 12m: 48.5 vs 24m, p= 0.012). The majority (70%) of pts treated < 12m stopped treatment due to progression (57% LM, 100% LD). Similarly, 58% of pts who received ≥ 12m of mx stopped for progression, but with a smaller proportion of LD pts (57% LM, 67% LD) compared to the < 12m cohort. There was no difference in PFS2 in pts that progressed or started subsequent treatment on or within 60 days of stopping mx vs those that progressed ≥ 60 days off therapy (mPFS2 21.7m vs 17.2m; p=0.16) with similar findings by mx type (mPFS2: LM 22.1m, LD 15.0m; p=0.054).

Conclusion: Our data show that real-world trends in mx therapy are discordant with those seen in large clinical trials, with only 61.5% of total pts completing ≥12m of mx therapy. Additionally, progression off mx was not associated with significantly worse outcomes with subsequent therapies compared to progression on mx in this cohort, though this analysis was limited by sample size. LM was associated with longer TTNT than LD on unadjusted analysis, however, this is likely confounded by the increased proportion of high-risk pts receiving LD in our cohort (presumably due to patient/provider’s preference for aggressive therapy to combat poor risk disease). Unfortunately, this approach proved suboptimal, suggesting that cytogenetic and biologic (functional) risk are the primary drivers of outcomes, and that these pts continue to represent a clear unmet need that should be addressed in prospective clinical trials.

Barry Paul, MD, MS: Bristol-Myers Squibb - Research Funding; Abbvie - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)